Short Interest in Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Decreases By 38.3%

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) saw a large drop in short interest during the month of April. As of April 30th, there was short interest totaling 36,638 shares, a drop of 38.3% from the April 15th total of 59,393 shares. Based on an average daily volume of 97,175 shares, the short-interest ratio is presently 0.4 days. Currently, 1.4% of the company’s shares are short sold.

Cyclacel Pharmaceuticals Stock Down 5.1%

Shares of NASDAQ:BGMS traded down $0.05 during trading on Friday, reaching $1.00. 14,800 shares of the company traded hands, compared to its average volume of 68,712. Cyclacel Pharmaceuticals has a 52-week low of $0.73 and a 52-week high of $34.65. The firm’s fifty day simple moving average is $0.99. The stock has a market capitalization of $5.50 million, a price-to-earnings ratio of -0.22 and a beta of -0.49.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.